Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells.
about
Analysis of bacterial biofilms using NMR-based metabolomicsThe carbon monoxide releasing molecule CORM-2 attenuates Pseudomonas aeruginosa biofilm formationSelective labelling and eradication of antibiotic-tolerant bacterial populations in Pseudomonas aeruginosa biofilms.Regulation of Pseudomonas aeruginosa Virulence by Distinct Iron SourcesInvolvement of iron in biofilm formation by Staphylococcus aureusThe complex interplay of iron, biofilm formation, and mucoidy affecting antimicrobial resistance of Pseudomonas aeruginosaMimicking the host and its microenvironment in vitro for studying mucosal infections by Pseudomonas aeruginosa.Hfe deficiency impairs pulmonary neutrophil recruitment in response to inflammation.The Pseudomonas aeruginosa type III translocon is required for biofilm formation at the epithelial barrier.Revealing the dynamics of polymicrobial infections: implications for antibiotic therapy.Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells.Haemophilus responses to nutritional immunity: epigenetic and morphological contribution to biofilm architecture, invasion, persistence and disease severity.Iron supplementation does not worsen respiratory health or alter the sputum microbiome in cystic fibrosisMannitol enhances antibiotic sensitivity of persister bacteria in Pseudomonas aeruginosa biofilms.Using non-enzymatic chemistry to influence microbial metabolismDissection of the cis-2-decenoic acid signaling network in Pseudomonas aeruginosa using microarray technique.Hacking into bacterial biofilms: a new therapeutic challengeIron acquisition in the cystic fibrosis lung and potential for novel therapeutic strategies.Establishment of a multi-species biofilm model and metatranscriptomic analysis of biofilm and planktonic cell communities.Compromised Defenses: Exploitation of Epithelial Responses During Viral-Bacterial Co-Infection of the Respiratory TractIron and CF-related anemia: expanding clinical and biochemical relationships.Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.The role of iron in pulmonary pathology.The Haemophilus influenzae Sap transporter mediates bacterium-epithelial cell homeostasis.Respiratory syncytial virus infection enhances Pseudomonas aeruginosa biofilm growth through dysregulation of nutritional immunity.Simultaneous Antibiofilm and Antiviral Activities of an Engineered Antimicrobial Peptide during Virus-Bacterium Coinfection.Eradication of Pseudomonas aeruginosa biofilms on cultured airway cells by a fosfomycin/tobramycin antibiotic combination.Ferrous iron is a significant component of bioavailable iron in cystic fibrosis airways.A Survival Strategy for Pseudomonas aeruginosa That Uses Exopolysaccharides To Sequester and Store Iron To Stimulate Psl-Dependent Biofilm Formation.Role of lung iron in determining the bacterial and host struggle in cystic fibrosis.Iron-regulated expression of alginate production, mucoid phenotype, and biofilm formation by Pseudomonas aeruginosa.Update in cystic fibrosis 2009.Microbial siderophores: a mini review.The impact of transition metals on bacterial plant disease.Novel approaches to the development of anti-sepsis drugs.BqsR/BqsS constitute a two-component system that senses extracellular Fe(II) in Pseudomonas aeruginosa.Biofilm, pathogenesis and prevention--a journey to break the wall: a review.Thalassosamide, a Siderophore Discovered from the Marine-Derived Bacterium Thalassospira profundimaris.The 'liaisons dangereuses' between iron and antibiotics.
P2860
Q26851303-90E4BB48-0EA5-4C47-B2B8-62B40661427CQ27304414-068DF59A-53A6-4DD6-9F49-EB385A440A6FQ27331155-D3E6F1C6-3CD5-4156-AD61-F920801DDB57Q28066690-3B7151DC-3BB3-4D43-B536-9101D219DC61Q28481681-2810991C-101E-4BD1-9BD6-AF8460526EC9Q33856134-DD35E579-1625-4F73-8534-B3A4FA914C7AQ33897664-27023565-3A55-4906-8055-CAD7157F1603Q34321351-6C54CD16-FF86-4D7E-B8A0-86FEC69479BFQ34466475-83446FB3-CFD4-4033-9ADB-649FE88C6C64Q34554419-BD0D9C8B-CB7A-43F1-BA6E-2AA7D80AA0E6Q34710667-F2B31B79-3B4B-484E-99D2-02A92FDF89E8Q35018104-33911D79-CB38-42B3-8E9E-4D4B37A16C58Q35065959-BD968B6E-ED0C-4858-8FE1-6FA40DBF9822Q35071144-B7852264-52CB-4515-A588-DF365C00686BQ35235881-922717D2-DBA2-4910-A278-C28969107787Q35545579-725DB043-7D30-4F46-966C-1333D61E3264Q35574148-EA8C82FE-A57D-48DA-A707-3FAB7C655D2CQ35862783-5C1ECE44-F837-4B65-ACE9-E32D3E286C53Q35996425-0A0E98A8-17EA-48E2-8BBA-808334757269Q36134249-9EF6FEC2-DF49-44D8-8678-3BE56D30A3A0Q36144584-A76BF4CC-6C29-41EB-B635-48576DE3E98CQ36288672-D15CE7D8-03D4-483C-9DE4-296902DE781BQ36308077-19BB58BB-5AB5-4B44-BF05-7FE81814408EQ36336719-0506538A-E137-4F0D-9D6C-3AAFF09DCDFAQ36506110-7FED0E87-ED9E-4537-B6B5-5B6975E4463BQ36598940-2CF7DBC3-70B6-42D4-BEF6-BB8866160D0FQ36956087-F9FD23A3-7EB7-4AEF-9412-43D248E0CE30Q37080915-049E388E-6C8B-4D99-9552-AE0A726EC0B6Q37120257-8433183D-F770-4BAC-AE10-14B09439F436Q37343254-1189CFB1-90C3-4ABB-B0BF-873569A4E0B4Q37584900-909EB069-CAB7-40C1-BFBC-E4F263EA3C88Q37631512-158CDF8D-3629-4A9F-8D58-05FF673A275FQ37704053-9900C29E-AAF2-424B-B567-6C98566C25B5Q38021726-DB88F7C1-6F18-4E80-B390-BE72D00E08CBQ38047325-8D1BDD15-9C4F-42BF-A75C-975F874CC0E5Q38201746-0CE2745C-DD76-4982-AD9F-743AC475719EQ38329253-5640C4C0-60C8-4986-A538-72153CB696CAQ38561433-64214987-AF34-4A2A-A958-5FEF6D533A42Q38608624-F708B066-5D63-42F7-AA4A-8E2FC4B5A529Q38761978-BA6913A3-5D43-4A90-B831-8010934798B8
P2860
Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tobramycin and FDA-approved ir ...... ilms on cystic fibrosis cells.
@en
Tobramycin and FDA-approved ir ...... ilms on cystic fibrosis cells.
@nl
type
label
Tobramycin and FDA-approved ir ...... ilms on cystic fibrosis cells.
@en
Tobramycin and FDA-approved ir ...... ilms on cystic fibrosis cells.
@nl
prefLabel
Tobramycin and FDA-approved ir ...... ilms on cystic fibrosis cells.
@en
Tobramycin and FDA-approved ir ...... ilms on cystic fibrosis cells.
@nl
P2093
P2860
P921
P356
P1476
Tobramycin and FDA-approved ir ...... ilms on cystic fibrosis cells.
@en
P2093
Bruce A Stanton
George A O'Toole
Sophie Moreau-Marquis
P2860
P304
P356
10.1165/RCMB.2008-0299OC
P577
2009-01-23T00:00:00Z